Xcenda GmbH
    Industry / private company
    
    
        Location: 
        Hannover,
        
                Germany (DE)
                
    
 
        
    
    
    
    
    
    
    
        
    
        
    
        
    
    
    
        
            
                
  
  Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracereoral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care (2022)
  Huttner H, Gerner S, Kuramatsu J, Connolly SJ, Beyer-Westendorf J, Demchuk AM, Middeldorp S, et al.
  Journal article
            
                
  
  ANDEXANET ALFA VERSUS USUAL CARE IN PATIENTS WITH DOAC ASSOCIATED INTRACEREBRAL HEMORRHAGE: A PROPENSITY-SCORE BASED HISTORICAL COMPARISON OF PATIENTS FROM ANNEXA4 AND RETRACEII (2020)
  Huttner H, Gerner S, Connolly S, Middeldorp S, Milling T, Beyer-Westendorf J, Altevers J, et al.
  Conference contribution